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Background
Rupatadine is a second generation antihistamine H1 and
antagonist of PAF for the treatment of allergic rhinitis
and urticaria for which a new pediatric oral solution is
now available for children between 6-11 y/o.
Objectives
1) To optimize the dose regime in children between
2 to 5 y/o old to reach similar plasma concentrations to
children of 6-11 y/o with allergic rhinitis.
2) To build a new population pharmacokinetic
(popPK) model in children including all ages (2-11 y/o)
to evaluate if the proposed regimen, as a function of
weight, is adequate to reach rupatadine exposure similar
to adults and ≥ 12 y/o.
Methods
A popPK model was developed, using data from 6-11 y/o
study (STD I) including 11 patients with full PK profile
in allergic rhinitis. A second study (STD2) including
2-5 y/o was optimal designed based on the parameters
estimated from STD I, assuming: inclusion of < 40 chil-
dren, < 5 samples per child in the shortest time window.
A final popPK model was built for children 2-11 years.
Influence of different covariates on model parameters
was also evaluated. PopPK modeling and simulation was
performed in NONMEM and optimal design in WIN-
POP software.
Results
The dose administered in STD II was 2.5 mg/kg (weight
10-25 kg) or 5 mg/kg (weight > 25 kg) and 3 samples
per child were needed in a 2h time window. A two-
compartmental model with first-order absorption and
elimination where clearance depends on weight fitted
the data for 2-11 y/o children. Mean (SD) estimates of
parameters obtained by noncompartmental analysis of
the steady-state simulated plasma concentrations for
both subsets of children were similar: Cmax, 2.54(1.26)
vs 1.96(0.52) ng/mL; AUC, 10.74(3.09) vs 10.38(4.31)
ng/mL/h; t1/2, 12.28(3.09) vs 15.94(4.09), for children
6-11 y/o and children 2-5 y/o, respectively.
Conclusion
A popPK model for rupatadine was used in the design
of a new clinical study. Rupatadine clearance in children
2-11 years increases with age. The used range of doses
in children provides similar exposure to rupatadine to
that associated with efficacy and safety in adults and
adolescents ≥ 12 y/o.
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